Article
Cardiac & Cardiovascular Systems
Siddhartha G. Kapnadak, Eric D. Morrell, Travis Hee Wai, Christopher H. Goss, Pali D. Shah, Christian A. Merlo, Ramsey R. Hachem, Kathleen J. Ramos
Summary: This study investigated the practices of azithromycin use among lung transplant providers internationally. The results showed significant variations in indications, timing, and dosing of azithromycin, with even inconsistencies within the same center. Most providers initiated azithromycin after the occurrence of risk factors and/or events related to chronic lung allograft dysfunction (CLAD).
JOURNAL OF HEART AND LUNG TRANSPLANTATION
(2022)
Article
Infectious Diseases
Hugo Testaert, Margaux Bouet, Florent Valour, Anne Gigandon, Marie -Edith Lafon, Francois Philit, Agathe Senechal, Jean-Sebastien Casalegno, Elodie Blanchard, Jerome Le Pavec, Florence Ader
Summary: This study analysed the impact of antimicrobial treatments on functional outcomes in adult lung transplant recipients with RSV-confirmed infection. It was found that 28.8% of recipients developed new allograft dysfunction at 3 months post-infection. Ribavirin treatment and azithromycin prophylaxis did not prevent decline in lung function.
CLINICAL MICROBIOLOGY AND INFECTION
(2021)
Article
Respiratory System
Auke E. S. de Zwart, Annelies Riezebos-Brilman, Gerton A. Lunter, Ewald C. U. Neerken, Coretta C. van Leer-Buter, Jan-Willem C. Alffenaar, Anna P. van Gemert, Michiel E. Erasmus, Christiaan T. Gan, Huib A. M. Kerstjens, Judith M. Vonk, Erik A. M. Verschuuren
Summary: The social distancing measures during COVID-19 led to a reduction in respiratory virus infection rates, which correlated with less decline in lung function, fewer episodes of TDLF, and possibly lower incidence of CLAD in lung transplant recipients.
EUROPEAN RESPIRATORY JOURNAL
(2022)
Review
Immunology
Xingqiang Lai, Xin Zheng, James M. Mathew, Lorenzo Gallon, Joseph R. Leventhal, Zheng Jenny Zhang
Summary: Despite advances in post-transplant management, the long-term survival rate of kidney grafts and patients has not improved significantly, as around four in ten transplants fail within ten years due to CKTR. Early detection and effective treatments for CKTR remain challenges, while the development of high throughput biotechnologies offers potential for rapid identification of new biomarkers for diagnosis. Emerging novel therapeutic strategies hold promise for improving long-term graft and patient survival.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Jesper Romhild Davidsen, Christian B. Laursen, Mikkel Hojlund, Thomas Kromann Lund, Klaus Nielsen Jeschke, Martin Iversen, Anna Kalhauge, Elisabeth Bendstrup, Jorn Carlsen, Michael Perch, Daniel Pilsgaard Henriksen, Hans Henrik Lawaetz Schultz
Summary: This study found that pleural thickening identified by lung ultrasound may serve as a potential surrogate marker to distinguish restrictive allograft syndrome (RAS) from bronchiolitis obliterans syndrome (BOS) in chronic lung allograft dysfunction (CLAD) patients after lung transplant. This discovery provides a new method for clinical diagnosis of CLAD patients post lung transplant.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Critical Care Medicine
Jarrod E. Dalton, Carli J. Lehr, Paul R. Gunsalus, Lyla Mourany, Maryam Valapour
Summary: This study examined the performance of models predicting waitlist and posttransplant survival in lung transplant allocation. The results showed that different models had similar performance in predicting waitlist and posttransplant survival, and using alternative modeling strategies and contemporary cohorts did not improve the models' performance in determining access to lung transplant.
Review
Pharmacology & Pharmacy
Vincent J. Venditto, David J. Feola
Summary: Drug carriers for macrolide antibiotics show promise in treating inflammatory conditions and have the potential to improve drug stability and reduce adverse reactions.
ADVANCED DRUG DELIVERY REVIEWS
(2022)
Review
Medicine, General & Internal
Christophe Pison, Adrien Tissot, Eric Bernasconi, Pierre-Joseph Royer, Antoine Roux, Angela Koutsokera, Benjamin Coiffard, Benjamin Renaud-Picard, Jerome Le Pavec, Pierre Mordant, Xavier Demant, Thomas Villeneuve, Jean-Francois Mornex, Simona Nemska, Nelly Frossard, Olivier Brugiere, Valerie J. Siroux, Benjamin Marsland, Aurore Foureau, Karine Botturi, Eugenie Durand, Johann Pellet, Richard Danger, Charles Auffray, Sophie Brouard, Laurent Nicod, Antoine Magnan
Summary: SysCLAD is a research aiming to predict chronic lung allograft dysfunction (CLAD), which involves investigating various factors including clinical data, assessment of airway microbiota, air pollution studies, activation of immune cells, secretion of matrix metalloproteinase-9 by T cells, subpopulations of T and B cells, genome polymorphisms, blood transcriptome, plasma proteome studies, and MSK1 expression to develop predictors of CLAD.
FRONTIERS IN MEDICINE
(2023)
Review
Biochemistry & Molecular Biology
Dalila Cavallaro, Marco Guerrieri, Stefano Cattelan, Gaia Fabbri, Sara Croce, Martina Armati, David Bennett, Antonella Fossi, Luca Voltolini, Luca Luzzi, Alberto Salvicchi, Piero Paladini, Adriano Peris, Miriana d'Alessandro, Paolo Cameli, Elena Bargagli, Tuscany Transplant Group, Laura Bergantini
Summary: Bronchiolitis obliterans syndrome is the most common form of CLAD, and its pathogenesis and markers play a crucial role in early diagnosis and treatment.
Article
Medicine, General & Internal
Giorgia Sulis, Brice Batomen, Anita Kotwani, Madhukar Pai, Sumanth Gandra
Summary: The study indicates a significant increase in antibiotic sales, particularly azithromycin, during the peak phase of the first COVID-19 epidemic wave in India, highlighting the urgent need for antibiotic stewardship measures.
Article
Critical Care Medicine
Yiming Wang, Steven L. Taylor, Jocelyn M. Choo, Lito E. Papanicolas, Rebecca Keating, Kate Hindmarsh, Rachel M. Thomson, Lucy Morgan, Geraint B. Rogers, Lucy D. Burr
Summary: Does long-term macrolide use affect the carriage of resistance within the oropharyngeal microbiota in people with chronic respiratory conditions and the risk of onward transmission to their close contacts?
Article
Critical Care Medicine
Michael P. Combs, David S. Wheeler, Jenna E. Luth, Nicole R. Falkowski, Natalie M. Walker, John R. Erb-Downward, Vibha N. Lama, Robert P. Dickson
Summary: The characteristics of the respiratory microbiome in healthy lung transplant recipients within the first year of transplantation have a significant impact on subsequent CLAD-free survival, with an increased lung bacterial burden predicting chronic rejection and death. The lung microbiome represents an understudied and potentially modifiable risk factor for lung allograft dysfunction.
LANCET RESPIRATORY MEDICINE
(2021)
Article
Respiratory System
Micheal C. McInnis, Jin Ma, Gauri Rani Karur, Christian Houbois, Liran Levy, Jan Havlin, Eyal Fuchs, Jussi Tikkanen, Chung-Wai Chow, Ella Huszti, Tereza Martinu
Summary: In this study, a machine learning computed tomography (CT) lung texture analysis tool was used for phenotyping and prognostication of chronic lung allograft dysfunction (CLAD) in lung transplant recipients. The results showed that machine learning could effectively distinguish different CLAD phenotypes, and the associated parameters were able to predict the risk of graft failure.
EUROPEAN RESPIRATORY JOURNAL
(2022)
Article
Cardiac & Cardiovascular Systems
Wai Wong, Brandy Johnson, Pi Chun Cheng, Maureen B. Josephson, Katsuhide Maeda, Robert A. Berg, Steven M. Kawut, Michael O. Harhay, Samuel B. Goldfarb, Nadir Yehya, Adam S. Himebauch
Summary: This study aimed to investigate the impact of grade 3 PGD within 48 or 72 hours on CLAD-free survival following pediatric lung transplantation. The study found that the occurrence of grade 3 PGD within 48 or 72 hours was associated with shorter CLAD-free survival, and gender may be a modifier of this association.
JOURNAL OF HEART AND LUNG TRANSPLANTATION
(2023)
Article
Chemistry, Multidisciplinary
Kiran Chaudhari, Anil Gohar, Stijn Claerhout, Rakesh Ganorkar
Summary: Controlling isomeric impurities in a key raw material is crucial for obtaining pure isomer-free targeted active pharmaceutical ingredient (API) in downstream processing. This study presents a scalable process for preparing substantially pure clarithromycin 9-(E)-oxime, with less than 1.2% of the (Z)-isomer, without the need for time-consuming purification steps. The pure clarithromycin 9-(E)-oxime can be converted into the pure 9a-lactam scaffold, and other impurities are also identified and controlled. The fine-tuned process allows for large-scale production of potential APIs derived from this scaffold.